Miller-Rich Nancy
SEC insider (Form 3/4/5 filer). CIK 0001735084. Director at 4D Molecular Therapeutics, Inc. (FDMT) and 1 other issuer. 8 reported Form 4/5 transactions since Sep 2024; latest on Jun 17, 2026. Located in LEXINGTON, MA.
Companies Miller-Rich Nancy has filed insider reports for
- 4D Molecular Therapeutics, Inc. (FDMT): Director
- Aldeyra Therapeutics, Inc. (ALDX): Director
Miller-Rich Nancy
CIK: 0001735084
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jun 17, 2026FDMT
4D Molecular Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
50K shares- - Jun 9, 2026ALDX
Aldeyra Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
3.3K shares- - Jun 9, 2026ALDX
Aldeyra Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
70K shares- - Jun 17, 2025FDMT
4D Molecular Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
22.5K shares- - Jun 10, 2025ALDX
Aldeyra Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
2.4K shares- - Jun 10, 2025ALDX
Aldeyra Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
62.7K shares- - Apr 12, 2023ALDX
Aldeyra Therapeutics, Inc.
PurchaseDirect509 shares at avg. $10.13$5K - May 3, 2021ALDX
Aldeyra Therapeutics, Inc.
PurchaseDirect413 shares at avg. $12.81$5K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  FDMT 4D Molecular Therapeutics, Inc. | Award Stock Option (Right to Buy) | 50,000 | - | - | Direct |
| Jun 9, 2026 |  ALDX Aldeyra Therapeutics, Inc. | Award Stock Option (Right to Buy) | 3,318 | - | - | Direct |
| Jun 9, 2026 | ALDX Aldeyra Therapeutics, Inc. | Award Stock Option (Right to Buy) | 70,000 | - | - | Direct |
| Jun 17, 2025 | FDMT 4D Molecular Therapeutics, Inc. | Award Stock Option (Right to Buy) | 22,500 | - | - | Direct |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | Award Stock Option (Right to Buy) | 2,413 | - | - | Direct |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | Award Stock Option (Right to Buy) | 62,728 | - | - | Direct |
| Apr 12, 2023 | ALDX Aldeyra Therapeutics, Inc. | Purchase | 509 | $10.13 | $5,156 | Direct |
| May 3, 2021 | ALDX Aldeyra Therapeutics, Inc. | Purchase | 413 | $12.81 | $5,291 | Direct |
1-8 of 8 transactions